昭衍新药
(603127)
| 流通市值：124.84亿 | | | 总市值：148.40亿 |
| 流通股本：6.30亿 | | | 总股本：7.49亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,018,333,771.81 | 1,335,156,050.4 | 849,356,544.11 | 324,809,103.67 |
| 营业收入 | 2,018,333,771.81 | 1,335,156,050.4 | 849,356,544.11 | 324,809,103.67 |
| 二、营业总成本 | 1,763,748,341.31 | 1,227,734,251.03 | 753,062,458.9 | 293,294,646.96 |
| 营业成本 | 1,444,560,234.36 | 968,251,629.5 | 591,423,436.78 | 218,156,989.73 |
| 税金及附加 | 8,981,402.37 | 6,894,612.65 | 5,384,649.37 | 2,369,721.32 |
| 销售费用 | 27,881,056.45 | 19,402,507.49 | 12,163,059.33 | 5,850,463.87 |
| 管理费用 | 289,180,575.62 | 236,735,760.07 | 156,350,663.29 | 71,961,656.69 |
| 研发费用 | 92,918,280.66 | 71,085,657.06 | 47,839,663.09 | 22,967,298.39 |
| 财务费用 | -99,773,208.15 | -74,635,915.74 | -60,099,012.96 | -28,011,483.04 |
| 其中:利息费用 | 2,448,073.47 | 1,827,953.64 | 1,248,564.49 | 653,474.98 |
| 其中:利息收入 | 103,230,766.43 | 82,526,990.66 | 61,632,134.02 | 29,068,900.75 |
| 加:公允价值变动收益 | -127,048,597.78 | -190,401,449.68 | -257,190,170.68 | -310,012,920.11 |
| 加:投资收益 | 36,011,545.69 | 31,620,189.62 | 28,019,180.74 | 6,972,038.25 |
| 资产处置收益 | -48,130.43 | -468,673.84 | -468,673.84 | - |
| 资产减值损失(新) | -66,540,016.67 | -25,480,216.62 | -45,213,931.95 | -26,264,433 |
| 信用减值损失(新) | -19,140,159.62 | -11,477,062.92 | -8,166,657.57 | -1,868,335.27 |
| 其他收益 | 26,527,237.43 | 19,124,400.35 | 9,571,426.79 | 6,650,918.69 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 104,347,309.12 | -69,661,013.72 | -177,154,741.3 | -293,008,274.73 |
| 加:营业外收入 | 223,456.84 | 96,166.74 | 109,059.02 | 10,364.83 |
| 减:营业外支出 | 531,692.34 | 327,422.81 | 305,425.03 | 132,105.74 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 104,039,073.62 | -69,892,269.79 | -177,351,107.31 | -293,130,015.64 |
| 减:所得税费用 | 34,284,009.72 | 4,351,740.15 | -5,112,791.17 | -19,766,412.57 |
| 六、净利润 | 69,755,063.9 | -74,244,009.94 | -172,238,316.14 | -273,363,603.07 |
| 持续经营净利润 | 69,755,063.9 | -74,244,009.94 | -172,238,316.14 | -273,363,603.07 |
| 归属于母公司股东的净利润 | 74,075,384.59 | -70,307,075.11 | -169,742,640.65 | -272,222,474.99 |
| 少数股东损益 | -4,320,320.69 | -3,936,934.83 | -2,495,675.49 | -1,141,128.08 |
| (一)基本每股收益 | 0.1 | -0.09 | -0.23 | -0.36 |
| (二)稀释每股收益 | 0.1 | -0.09 | -0.23 | -0.36 |
| 八、其他综合收益 | -51,041,084.41 | -4,859,185.75 | 3,024,917.86 | 863,793.54 |
| 归属于母公司股东的其他综合收益 | -51,041,084.41 | -4,859,185.75 | 3,024,917.86 | 863,793.54 |
| 九、综合收益总额 | 18,713,979.49 | -79,103,195.69 | -169,213,398.28 | -272,499,809.53 |
| 归属于母公司股东的综合收益总额 | 23,034,300.18 | -75,166,260.86 | -166,717,722.79 | -271,358,681.45 |
| 归属于少数股东的综合收益总额 | -4,320,320.69 | -3,936,934.83 | -2,495,675.49 | -1,141,128.08 |
| 公告日期 | 2025-03-29 | 2024-10-31 | 2024-08-31 | 2024-04-30 |
| 审计意见(境内) | 标准无保留意见 | | | |